Outcomes associated with the intention of loco-regional therapy prior to living donor liver transplantation for hepatocellular carcinoma

doi:10.4240/wjgs.v12.i1.17

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6684)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-2) series.

Item

Count

PDF

318

WORD

178

HTML

2938

Figures (1-4)

673

Tables (1-2)

272

Sum=4379

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

775

Download

1530

Sum=2305

Jan 27, 2020 (publication date) through Nov 26, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Surg. Jan 27, 2020; 12(1): 17-27
Published online Jan 27, 2020. doi: 10.4240/wjgs.v12.i1.17

Full Size Figure Download Figure

Figure 3 Comparison of recurrence-free survival curves based on the definition of profound tumor necrosis. The recurrence-free survival in patients with profound tumor necrosis (TN) was significantly better than those without profound TN (P = 0.01). TN: Tumor necrosis.

Citation: Wu TH, Wang YC, Cheng CH, Lee CF, Wu TJ, Chou HS, Chan KM, Lee WC. Outcomes associated with the intention of loco-regional therapy prior to living donor liver transplantation for hepatocellular carcinoma. World J Gastrointest Surg 2020; 12(1): 17-27
URL: https://www.wjgnet.com/1948-9366/full/v12/i1/17.htm
DOI: https://dx.doi.org/10.4240/wjgs.v12.i1.17